Geron Showcases New ASH 2025 Data Highlighting RYTELO's Durable Efficacy And Survival Trends Across LR-MDS And Myelofibrosis
Benzinga Newsdesk 10 months ago
BiotechNewsGeneral
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independence in lower-risk MDS
Long-term follow-up analysis from IMerge supports favorable survival trends and durable clinical benefit in LR-MDS
Additional analyses in myelofibrosis and advanced MDS/AML offer important context for understanding the biology of telomerase inhibition
FOSTER CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced new data presented at the 67th American Society of Hematology (ASH) 2025 Annual Meeting being held in Orlando, FL. Collectively, the oral and poster presentations reinforce the growing body of evidence supporting the potential of RYTELO® (imetelstat), Geron's first-in-class telomerase inhibitor, across lower-risk myelodysplastic syndromes/neoplasms (LR-MDS) and myelofibrosis (MF).